Abstract

Oral malignant melanoma (OMM) is the most common canine melanocytic neoplasm. Overlap between the somatic mutation profiles of canine OMM and human mucosal melanomas suggest a shared UV-independent molecular aetiology. In common with human mucosal melanomas, most canine OMM metastasise. There is no reliable means of predicting canine OMM metastasis, and systemic therapies for metastatic disease are largely palliative. Herein, we employed exon microarrays for comparative expression profiling of FFPE biopsies of 18 primary canine OMM that metastasised and 10 primary OMM that did not metastasise. Genes displaying metastasis-associated expression may be targets for anti-metastasis treatments, and biomarkers of OMM metastasis. Reduced expression of CXCL12 in the metastasising OMMs implies that the CXCR4/CXCL12 axis may be involved in OMM metastasis. Increased expression of APOBEC3A in the metastasising OMMs may indicate APOBEC3A-induced double-strand DNA breaks and pro-metastatic hypermutation. DNA double strand breakage triggers the DNA damage response network and two Fanconi anaemia DNA repair pathway members showed elevated expression in the metastasising OMMs. Cross-validation was employed to test a Linear Discriminant Analysis classifier based upon the RT-qPCR-measured expression levels of CXCL12, APOBEC3A and RPL29. Classification accuracies of 94% (metastasising OMMs) and 86% (non-metastasising OMMs) were estimated.

Highlights

  • Oral malignant melanomas (OMMs) are neoplastic proliferations of melanocytes, and are the most common oral tumour in dogs[1]

  • Putative activating mutations in Kit have been described in 7–16% of human mucosal melanomas[28,29] and in 12% of canine OMM30, and mutations in NRAS have been reported in 3.9% of canine OMMs3 and in 10–22% of human mucosal melanomas[31,32,33]

  • At the present time there is no means to accurately predict if an individual OMM is one of the significant proportion of tumours that will metastasise, and metastasis is commonly underestimated during tumour staging due to a failure to sample all appropriate lymph nodes, and/or a failure of detection by standard cytology or histopathology

Read more

Summary

Introduction

Oral malignant melanomas (OMMs) are neoplastic proliferations of melanocytes, and are the most common oral tumour in dogs[1]. Where OMM metastasis to regional lymph nodes occurs, it is not always detected by examination of the mandibular and retropharyngeal lymph nodes[16,17]. Human OMMs are aggressive rapidly growing, invasive tumours that display metastatic rates of 66% (regional lymph nodes22), 53% (lung23), 36% (bone23), and 20% (liver and brain23), respectively. Around 50% of human cutaneous melanomas have an activating BRAF mutation[34], but BRAF mutations occur in only 4–9.5% of human mucosal melanomas[35,36], and have not been found in canine OMMs3

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call